SCHEMBL40810

SCHEMBL40810

C1CCCCNNNNCCC1

nearest known ligand 0.43

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1772457 1.00
SCHEMBL3077600 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL3079047 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL360309 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL2897919 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL3078484 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL3078185 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL3073379 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL3031889 1.00 ALDH1A1 (0.43) ALDH1A1
SCHEMBL3064137 1.00 ALDH1A1 (0.43) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121554629-B Preparation method and application of macrocyclic polyamine-based porous organic aerogel 浙江理工大学嵊州创新研究院有限公司 2026-05-12 CN claimed
EP-4688828-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF Jubilant DraxImage Inc. (CA) 2026-02-11 EP claimed
CN-115737845-B CD47 specific molecular imaging probe and preparation method and application thereof 上海交通大学医学院附属仁济医院 2025-05-13 CN claimed
US-12226494-B2 Pharmaceutical compositions comprising Gd-complexes and polyarylene additives BRACCO IMAGING S.P.A. (IT) 2025-02-18 US claimed
EP-4486395-A1 PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE Atoms for Cure GmbH (DE) 2025-01-08 EP claimed
WO-2024231837-A1 NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE UNIVERSITA' DEGLI STUDI DI TORINO (IT) 2024-11-14 WO claimed
WO-2024201255-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF JUBILANT DRAXIMAGE INC. (CA) 2024-10-03 WO claimed
EP-4404981-A1 RADIOPHARMACEUTICAL COMPLEX FOR IMAGING AND/OR LOCALIZING PSMA POSITIVE CELLS Scogif S.r.l. (IT) 2024-07-31 EP claimed
US-20240228663-A9 ANTI-CHITINASE-3-LIKE PROTEIN-1 (YKL-40) NEUTRALIZING ANTIBODY AND USES THEREOF Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C (TW) 2024-07-11 US claimed
US-20240165281-A1 DUAL MODE RADIOTRACER AND THERAPEUTICS UNIV MUENCHEN TECH (DE) 2024-05-23 US claimed
WO-1995009161-A1 HEPATOBILIARY MAGNETIC RESONANCE CONTRAST AGENTS BRACCO INTERNATIONAL B.V. (NL) 1995-04-06 WO claimed
EP-0545983-B1 INTERMEDIATES FOR CHELATING AGENTS WITH PREFIXED SYMMETRY AND PROCESS FOR THEIR PREPARATION BRACCO SPA (IT) 1994-10-26 EP claimed
US-5358704-A Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents BRISTOL-MYERS SQUIBB (US) 1994-10-25 US claimed
EP-0618910-A1 SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1994-10-12 EP claimed
US-5277895-A Nuclear magnetic resonance SCHERING AKTIENGESELLSCHAFT (DE) 1994-01-11 US claimed
EP-0545983-A1 INTERMEDIATES FOR CHELATING AGENTS WITH PREFIXED SYMMETRY AND PROCESS FOR THEIR PREPARATION. BRACCO SPA (IT) 1993-06-16 EP claimed
EP-0545511-A2 Process for the preparation of mono-N-substituted tetraazamacrocycles SCHERING AKTIENGESELLSCHAFT (DE) 1993-06-09 EP claimed
WO-1992004336-A1 INTERMEDIATES FOR CHELATING AGENTS WITH PREFIXED SYMMETRY AND PROCESS FOR THEIR PREPARATION BRACCO INDUSTRIA CHIMICA S.P.A. (IT) 1992-03-19 WO claimed
US-4915933-A Nuclear magnetic resonance THE UNIVERSITY OF NEW MEXICO (US) 1990-04-10 US claimed
EP-0325307-A2 Macrocyclic polyamine multifunctional lubricating oil additives EXXON RESEARCH AND ENGINEERING COMPANY (US) 1989-07-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240165281-A1 DUAL MODE RADIOTRACER AND THERAPEUTICS FOLH1, KLK3, PAICS ALDH1A1 1244/4885
US-12226494-B2 Pharmaceutical compositions comprising Gd-complexes and polyarylene additives GRN, GALC, ABCB11 ALDH1A1 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.